Regulatory – Alligator Bioscience

2023-11-06

Regulatory

Correction: Nomination Committee appointed in respect of AGM 2024 in Alligator Bioscience AB

The press release as of November 6, 2023 regarding the Nomination Committee appointed in respect of AGM 2024 incorrectly stated Hans-Peter O ...

2023-11-06

Regulatory

Lund, Sweden, November 6, 2023– Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation ...

2023-10-26

Regulatory

European Medicines Agency grants mitazalimab Orphan Designation in pancreatic cancer Technical Feasibility achieved in second collaboration ...

2023-09-29

Regulatory

During September 2023, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the exercise of ...

2023-08-21

Regulatory

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Medicines Agency (EMA) has granted Orphan De ...

2023-07-13

Regulatory

Positive second interim analysis from OPTIMIZE-1 Phase 2 study shows increase in ORR* and favorable DoR** suggesting durable benefits of mit ...

2023-06-30

Regulatory

During June 2023, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of the ...

2023-06-26

Regulatory

Continued follow-up on the futility analysis cohort (23 patients) showed deepening of tumor responses and an increase in Objective Response ...

2023-05-26

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...